Last edition
News about "SLEEP 2026"
Takeda's Oveporexton Improves Daily Function in Narcolepsy Type 1
Takeda’s phase 3 data show oveporexton improved daily function, cognition, and nighttime sleep in people with narcolepsy type 1. The results support the potential of the first orexin agonist therapy, with regulatory submissions currently under review.
SLEEP 2026 | 16/06/2026 | By News Bureau
Suven Life Sciences Announces 3 Poster Presentations on Samelisant
Suven Life Sciences showcases 3 posters on Samelisant (SUVN-G3031), including findings from the global phase 3 AWAKE Narcolepsy Study at SLEEP 2026.
SLEEP 2026 | 12/06/2026 | By News Bureau | 135
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy